| Literature DB >> 33662277 |
Samantha M Townsley1, Gina C Donofrio1, Ningbo Jian1, David J Leggat2, Vincent Dussupt1, Letzibeth Mendez-Rivera1, Leigh Anne Eller1, Lauryn Cofer1, Misook Choe3, Philip K Ehrenberg4, Aviva Geretz1, Syna Gift1, Rebecca Grande1, Anna Lee1, Caroline Peterson3, Mary Bryson Piechowiak1, Bonnie M Slike1, Ursula Tran1, M Gordon Joyce3, Ivelin S Georgiev5, Morgane Rolland1, Rasmi Thomas1, Sodsai Tovanabutra1, Nicole A Doria-Rose2, Victoria R Polonis4, John R Mascola2, Adrian B McDermott2, Nelson L Michael6, Merlin L Robb1, Shelly J Krebs7.
Abstract
Determining which immunological mechanisms contribute to the development of broad neutralizing antibodies (bNAbs) during HIV-1 infection is a major goal to inform vaccine design. Using samples from a longitudinal HIV-1 acute infection cohort, we found key B cell determinants within the first 14-43 days of viremia that predict the development of bNAbs years later. Individuals who develop neutralization breadth had significantly higher B cell engagement with the autologous founder HIV envelope (Env) within 1 month of initial viremia. A higher frequency of founder-Env-specific naive B cells was associated with increased B cell activation and differentiation and predictive of bNAb development. These data demonstrate that the initial B cell interaction with the founder HIV Env is important for the development of broadly neutralizing antibodies and provide evidence that events within HIV acute infection lead to downstream functional outcomes.Entities:
Keywords: B cells; HIV; acute infection; broadly neutralizing antibodies; founder envelope
Mesh：
Substances：
Year: 2021 PMID： 33662277 PMCID： PMC8245051 DOI： 10.1016/j.chom.2021.01.016
Source DB: PubMed Journal: Cell Host Microbe ISSN： 1931-3128 Impact factor: 21.023